Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of the Efficacy and Safety of Molindone Hydrochloride Extended-Release for the Treatment of Impulsive Aggression in Pediatric Patients With Attention Deficit/Hyperactivity Disorder in Conjunction With Standard ADHD Treatment

NCT02618434 is registered in ClinicalTrials.gov with Supernus Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02618434
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02618434 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of the Efficacy and Safety of Molindone Hydrochloride Extended-Release for the Treatment of Impulsive Aggression in Pediatric Patients With Attention Deficit/Hyperactivity Disorder in Conjunction With Standard ADHD Treatment
Lead sponsor
Supernus Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
February 16, 2016
Completion date
February 14, 2020
Enrollment
297 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

attention deficit hyperactivity disorder (adhd)